RAD BioMed Overview
RAD Biomed is an Israel-based private incubator that invests in early-stage biomedical and Hi-Tech start-ups. RAD Biomed invests in exciting new solutions at the earliest stages, providing a full set of operational and professional services, mentorship and industry connections. Rad Biomed was launched by the RAD Group, a group of independent companies that develop, manufacture, and market solutions for diverse segments of the networking and telecommunications industry. The RAD Group has decades of experience in guiding and nurturing start-ups as they grow towards commercial launch, sales growth, and successful exit, with nine Nasdaq IPOs and 10 M&As.
Latest News
growth-positive
A chance encounter at university led Dr. Eyal Orion to the Zisapel brothers’ RAD Biomed incubator, setting him on a path to found five medical device companies, including one sold for $100 million. This month, he achieved a second exit with the $497 million sale of Vectorious, developer of a heart failure–detecting sensor.
Vectorious, a medical device company founded by Dr. Eyal Orion, was acquired by Edwards Lifesciences for $497 million. The company developed a heart failure-detecting sensor, V-LAP, which is implanted in the heart to monitor pressure and provide early warnings of fluid congestion. This acquisition marks a significant milestone for Vectorious, which has been preparing for a pivotal clinical trial to gain FDA approval. The partnership with Edwards, which began with an investment in 2020, has grown into a full acquisition, allowing Vectorious to leverage Edwards expertise in navigating regulatory and medical ecosystems. The acquisition highlights the potential of Israeli innovation in the medical device sector.
Acquired-by
growth-positive
Global Pharma Company Exercises Rights for Exclusive Use of Everads Drug Delivery Technology in Specific Retinal Targets
Everads Therapy has announced a milestone achievement within its collaboration with a global pharmaceutical company. The pharmaceutical company has been granted exclusivity to utilize Everads suprachoroidal delivery technology for the development of specific ocular targets, in exchange for a milestone payment. Everads retains the right to continue using and licensing its technologies for other therapies. The company is optimistic that the collaboration will lead to a commercial license. Everads Therapy is a life sciences company focused on developing a revolutionary delivery system for suprachoroidal delivery of injectable therapies.
Partners
growth-positive
Belkin Laser announces $12.2 million raised in series B funding
Israeli medtech startup Belkin Laser has completed a $12.2 million series B financing round led by Rimonci Capital and Santen Ventures Inc. The company, which develops a one-second glaucoma treatment, has raised a total of $21.3 million in funding. Belkin Laser plans to use the capital to continue its clinical trials and launch new trials in Asia. The product is expected to enter the market in two years. The financing round included participation from BioLight Life Sciences, C-Mer Eye Care Holdings, and CR-CP Life Science Fund. Belkin Laser had previously raised $6.6 million from grants and a $2.5 million investment in a series A round led by ZIG Ventures.
Investment
growth-positive
VasQ™ External Support Awarded Breakthrough Device Designation by the FDA
The FDA has designated Laminate Medicals VasQ External Support for the creation of arteriovenous fistulas (AVF) in hemodialysis patients as a Breakthrough Device. This designation is expected to provide additional reimbursement for new technologies. The VasQ External Support has consistently demonstrated improvement over the standard of care for creating functional AVFs for hemodialysis treatment. The device is currently in a U.S. IDE pivotal clinical study and is expected to receive market clearance in the U.S. Laminate Medical Technologies is dedicated to making better fistulas for hemodialysis patients.
Customers
growth-positive
Zsquare Named A Silver Winner of the 2020 Edison Awards
Zsquare has been named a silver winner in the Medical/Dental category at the 2020 Edison Awards. Zsquare offers ultra-thin, flexible, high-resolution single-use endoscopes that eliminate the risk of infections caused by contaminated, reused endoscopes. The award recognizes Zsquare as a game-changing innovation in the medical field. The company aims to transform the way endoscopes are used worldwide and address the problem of cross-contamination. Zsquare is a privately-held medical device company based in Israel.
CustomersPartners
Team Members
3
Web & Social Links
| Website | www.radbiomed.com/ |
Locations
Raoul Wallenberg St 24, Tel Aviv-Yafo, Israel
Photos & Videos
No files yet
